Arthritis drug may reduce mortality in hospitalised COVID-19 patients - The Pharmaceutical Journal
Adding the rheumatoid arthritis drug, baricitinib, to another immunomodulatory treatment reduces the risk of death in hospitalised patients with severe COVID-19, the results from a major study suggest. Data from the ‘Randomised evaluation of COVID-19 therapy’…
Adding the rheumatoid arthritis drug, baricitinib, to another immunomodulatory treatment reduces the risk of death in hospitalised patients with severe COVID-19, the results from a major study sugges… [+3552 chars]
Read More
Other Stories in Health
- Dosa saree, Idli shirt and a pani puri watch? AI turns desi food into fashion
- Where and why men die younger: global data breaks it down
- 8 Best Foldable Rowing Machines, According to Editors and Certified Trainers
- Strawberry Lemon Cream Crepes {Grain-Free Options Included}
- What predicts belief in the afterlife? A massive global study has answers
- Getting active in midlife may boost brain resilience to Alzheimer’s
- May 2025 Cooking Challenge
- May 2025 Cooking Challenge
- TDP-43 dysfunction in brain blood vessels may drive Alzheimer's and ALS progression
.png)
